The development of an Internet-based course on dyslipidemias: A new form of continuing education for pharmacists

American Journal of Pharmaceutical Education

Volumn 65, Issue 1, 2001, Pages 13-19

  Olson, Kari L ^a   Schindel, Terri ^a   Geissler, Colin ^a   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012493834     PISSN: 00029459     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Browner, W.S., Baron, R.B., Solkowitz, S., Adler, L.J. and Gullion, D.S., "Physician management of hypercholesterolemia: A randomized trial on continuing medical education," West. J. Med., 1616, 572-578(1994).
2. Williamson, J.W., German, P.S., Weiss, R., Skinner, E.A. and Bowes, F., "Health science information management and continuing education of physicians: A survey of U.S. primary care practitioners and their opinion leaders," Ann. Intern. Med., 110, 151-160(1989).
3. Ketley, D. and Woods, K.L., "Impact of clinical trials on clinical practice: Example of thrombolysis for acute myocardial infarction," Lancet, 342, 891-894(1993).
4. Cohen, M.V., Byrne, M., Levine, B., Gutowski, T. and Adelson, R., "Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease," Circulation, 83, 1294-1304(1991).
5. Freemantle, N., Harvey, E.L., Wolf, F., Grimshaw, J.M., Grilli, R. and Bero L.A., "Printed educational materials: Effects on professional practice and health care outcomes (Cochrane Review)," in The Cochrane Library, 2, 1999. Oxford: Update Software.
6. Davis, D., O'Brien, M., Freemantle, N., Wolf, F.M., Mazmanian, P. and Taylor-Vaisey, A., "Impact of formal continuing medical education: Do conferences, workshops, rounds and other traditional continuing education activities change physician behavior or health care outcomes?" JAMA, 282, 867-874(1999).
7. Oxman, A.D., Thomson, M., Davis, D.A. and Haynes, B., "No magic bullets: A systematic review of 102 trials of interventions to improve professional practice," Can. Med. Assoc. J., 153, 1423-1431(1995).
8. Davis, D.A., Thomson, M., Oxman, A.D. and Haynes, B., "Evidence for the effectiveness of CME: A review of 50 randomized controlled trials," JAMA, 268, 1111-1117(1992).
9. Haynes, R.B., Davis, D.A., McKibbon, A. and Tugwell, P., "A critical appraisal of the efficacy of continuing medical education," JAMA, 251, 61-64(1984).
10. Davis, D.A., Thomson, M., Oxman, A.D. and Haynes, B., "Changing physician performance: A systematic review of the effect of continuing medical education strategies," JAMA, 274, 700-705(1995).
11. Davis, D., "Does CME work: An analysis of the effect of educational activities on physician performance or health care outcomes," Int. J. Psychiatry. Med., 28, 21-39(1998).
12. Bates, A.W., Technology, Open Learning and Distance Education, Routledge, London (1995).
13. Trinkle R., "Pharmacy continuing education available on the Internet," Pharmacother. 19, 909-921(1999).
14. Doucet, M.D., Purdy, R.A., Kaufman, D.M. and Languie, D.B., "Comparison of problem-based learning and lecture format in continuing medical education on headache diagnosis and management," Med. Educ. 32, 590-596(1998).
15. Rossett, A., Training Needs Assessment, Educational Technology Publications, Englewood Cliffs NJ (1987).
16. Frohlich, J., Fodor, G., McPherson, R., Genest, J. and Langner, N., "Recommendations for the management and treatment of dyslipidemia: Report of the working group on hypercholesterolemia and other dyslipidemias," Can. Med. Assoc. J., 162, 1441-1447(2000).
17. Tsuyuki, R.T., Johnson, J.A., Teo, K.K., Simpson, S.H., Ackman, M.L., Biggs, R.S., Cave, A.J., Chang, W.C., Dzavik, V., Farris, K.B., Galvin, D., Semchuk, W. and Taylor, J.G., for the SCRIP investigators., "Study of cardiovascular risk intervention by pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacists intervention program on serum cholesterol risk," Can. J. Cardiol., 16, (suppl F), 118F (2000).
18. Tsuyuki, R.T., Johnson, J.A., Teo, K.K., Ackman, M.L., Biggs, R.S., Cave, A.J., Chang, W.C., Dzavik, V., Farris, K.B., Galvin, D., Semchuk, W., Simpson, S.H. and Taylor, J.G., for the SCRIP investigators, "Study of cardiovascular risk intervention by pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacists intervention program on serum cholesterol risk," Ann. Pharmacother., 33, 910-919 (1999).
19. Health Canada., The Changing Face of Heart Disease and Stroke in Canada 2000, Government of Canada. Available from http://www.hcsc.gc.ca/main/lcdc/web/bcrdd/hdsc2000/pdf/card2ke.pdf
20. Stamler, J., Wentworth, D. and Neaton, J.D., "Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded," JAMA, 256, 2823-2828(1986).
21. Scandinavian Simvastatin Survival Study Group., "Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study," Lancet, 344, 1383-1389(1994).
22. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. and Brown, L., Warnica, J.W, Arnold, J.M., Wun, C.C., Davis, B.R. and Braunwald, E., "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels," N. Engl. J. Med, 334, 1001-1009(1996).
23. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group., "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels," N. Engl. J. Med., 339, 1349-1357(1998).
24. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard C.J., "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia," N. Engl. J. Med., 333, 1301-1307(1995).
25. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A, Langendorfer, A., Stein, E.A., Kruyer, W. and Gotto, A.M., "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels," JAMA, 279, 1615-1622(1998).
26. Pearson, T.A. and Peters, T.D., "The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient," Am. J. Cardiol., 80(8B), 45H-52H(1997).
27. Pearson, T.A., Laurora, I., Chu, H. and Kafonek, S., "The lipid treatment assessment project (L-TAP)," Arch. Intern. Med., 160, 459-467(2000).
28. Sueta C., Chowdhury, M., Boccuzzi, S.J., Smith, S.C., Alexander, C.M., Londhe, A., Lulla, A. and Simpson, R.J., "Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease," Am. J. Cardiol., 83, 1303-1307(1999).
29. Hepler, C.D. and Strand, L.M., "Opportunities and responsibilities in pharmaceutical care," Am. J. Hosp. Pharm., 47, 533-543(1990).
30. Miller, M.J. and Ortmeier, B.G., "Factors influencing the delivery of pharmacy services," Amer. Pharm., NS35, 39-45(1995).